H-J Bühring - JoVE Visualize

Showing results (51-60 of 103) with videos related to

Pageof 11

Sort By:

The Journal of Molecular and Cellular Immunology : JMCI|January 1, 1988

"Tolerization" of human T-helper cell clones by chronic exposure to alloantigen: culture conditions dictate autocrine proliferative status but not acquisition of cytotoxic potential and suppressor-induction capacityG Pawelec, T Brocker, F W Busch, et al.

Annals of the New York Academy of Sciences|July 19, 2001

Dendritic cell-based vaccines in patients with hematological malignanciesW Brugger, A Schneider, T Schammann, et al.

Blood|October 9, 1998

The sialomucin CD164 (MGC-24v) is an adhesive glycoprotein expressed by human hematopoietic progenitors and bone marrow stromal cells that serves as a potent negative regulator of hematopoiesisA C Zannettino, H J Bühring, S Niutta, et al.

Blut|March 1, 1987

HLA-class II antigens on human hematopoietic progenitorsF W Busch, M Langer, G Pawelec, et al.

Immunobiology|September 1, 1985

Specific antibodies elicited by antigen covalently linked to a synthetic adjuvantW G Bessler, B Suhr, H J Bühring, et al.

Annals of the New York Academy of Sciences|June 18, 1999

Expression of novel surface antigens on early hematopoietic cellsH J Bühring, M Seiffert, T A Bock, et al.

Hepato-Gastroenterology|March 1, 1997

Parameters predicting response to alpha-interferon treatment in chronic hepatitis CT Glück, R Seelig, S Dette, et al.

Blood|April 21, 2001

Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cellsM Seiffert, P Brossart, C Cant, et al.

Molecular Biotherapy|March 1, 1990

Lymphokine release, suppressor cell generation, cell surface markers, and cytotoxic activity in cancer patients receiving natural interleukin-2G Pawelec, U Schwuléra, H Lenz, et al.

Journal of Hematotherapy|June 1, 1999

Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS deviceM Schumm, P Lang, G Taylor, et al.

Pageof 11

Showing results (51-60 of 103) with videos related to

Sort By:

Pageof 11

The Journal of Molecular and Cellular Immunology : JMCI|January 1, 1988

"Tolerization" of human T-helper cell clones by chronic exposure to alloantigen: culture conditions dictate autocrine proliferative status but not acquisition of cytotoxic potential and suppressor-induction capacityG Pawelec, T Brocker, F W Busch, et al.

Annals of the New York Academy of Sciences|July 19, 2001

Dendritic cell-based vaccines in patients with hematological malignanciesW Brugger, A Schneider, T Schammann, et al.

Blood|October 9, 1998

The sialomucin CD164 (MGC-24v) is an adhesive glycoprotein expressed by human hematopoietic progenitors and bone marrow stromal cells that serves as a potent negative regulator of hematopoiesisA C Zannettino, H J Bühring, S Niutta, et al.

Blut|March 1, 1987

HLA-class II antigens on human hematopoietic progenitorsF W Busch, M Langer, G Pawelec, et al.

Immunobiology|September 1, 1985

Specific antibodies elicited by antigen covalently linked to a synthetic adjuvantW G Bessler, B Suhr, H J Bühring, et al.

Annals of the New York Academy of Sciences|June 18, 1999

Expression of novel surface antigens on early hematopoietic cellsH J Bühring, M Seiffert, T A Bock, et al.

Hepato-Gastroenterology|March 1, 1997

Parameters predicting response to alpha-interferon treatment in chronic hepatitis CT Glück, R Seelig, S Dette, et al.

Blood|April 21, 2001

Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cellsM Seiffert, P Brossart, C Cant, et al.

Molecular Biotherapy|March 1, 1990

Lymphokine release, suppressor cell generation, cell surface markers, and cytotoxic activity in cancer patients receiving natural interleukin-2G Pawelec, U Schwuléra, H Lenz, et al.

Journal of Hematotherapy|June 1, 1999

Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS deviceM Schumm, P Lang, G Taylor, et al.

Pageof 11